Names, evidence and limits.
Find the compound you are researching. Each note distinguishes a source’s statement from what it does not prove.
BPC-157
What FDA says about limited human safety information and compounding risks.
Read the evidence notes →GHK-Cu
FDA’s warning concerns injectable use. Keep product types and routes separate.
Read the evidence notes →Ipamorelin
FDA describes route-specific uncertainty and serious events reported in an intravenous study.
Read the evidence notes →Tesamorelin
The EGRIFTA WR label describes a specific indication, not general weight-loss use.
Read the evidence notes →Tirzepatide
Zepbound has specific weight-management and sleep-apnea indications. Compounded versions are separate.
Read the evidence notes →Semaglutide
Wegovy injection and tablets have different labeled populations and indications.
Read the evidence notes →Retatrutide
FDA says retatrutide is not a component of an approved drug and cannot be used in compounding under federal law.
Read the evidence notes →Glutathione
FDA documents endotoxin concerns with ingredient quality in compounded injectable products.
Read the evidence notes →Oxytocin
The injectable label describes obstetric uses and the need for trained observation, not wellness claims.
Read the evidence notes →NAD+
Included because readers research it alongside peptides. FDA warns about food-grade ingredients in sterile injectable products.
Read the evidence notes →Semax
FDA says human safety information is absent or limited for proposed routes.
Read the evidence notes →MOTS-c
FDA has not identified human exposure data for drug products containing MOTs-C.
Read the evidence notes →CJC-1295
FDA reports limited clinical data and serious events associated with the compound.
Read the evidence notes →Selank
FDA identifies important gaps in safety information for selank acetate.
Read the evidence notes →KPV
FDA has not identified human exposure data for KPV drug products.
Read the evidence notes →TB-500
FDA identifies TB-500 as a specific thymosin beta-4 fragment and notes missing human exposure data.
Read the evidence notes →Sermorelin
FDA’s 2013 Geref withdrawal determination is not approval of every compounded sermorelin claim.
Read the evidence notes →PT-141 / Bremelanotide
The Vyleesi label has a narrow HSDD indication and important cardiovascular limits.
Read the evidence notes →